8 gen 1998 anni - FDA approves Dako's immunohistochemical assay, Herceptest, for detection of HER2 protein, the target of trastuzamab (Herceptin), a genetically engineered treatment for metastatic breast cancer.

Aggiunto al nastro di tempo:

23 set 2017

0

0

310

New timeline

Data: